Latest Information Update: 23 Mar 2010
At a glance
- Originator Bayer
- Class Antihyperglycaemics
- Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 29 May 2002 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)